Event Overview
From May 5 to 7, 2026, local time, Vitafoods Europe, the world’s most influential event in nutrition and health, grandly opened in Barcelona, Spain. At this industry bellwether gathering more than 1,600 top companies from around the globe, Zhongchuang Yike (Shanghai) Biotechnology Co., Ltd. made a striking appearance with a clear positioning – "Metabolic Health Microbiome Solution Expert" – showcasing its end-to-end strength from proprietary strain screening to final application.
At a critical juncture where the industry is shifting from "concept addition" to "clinical evidence", Zhongchuang Yike not only brought rigorously validated star clinical strains, but also demonstrated postbiotic technologies that break through application limitations, injecting powerful innovation momentum into the evolving functional food market.
The Evidence Era: From "Counting CFUs" to "Proving Efficacy"
By 2026, the global probiotic market has completely moved past the crude phase of merely competing on "live bacteria counts" and entered a deeper stage of "evidence and efficacy". Consumers no longer pay for hollow "billions of CFUs" printed on packaging; instead, they prefer products backed by human trials and scientific validation. Zhongchuang Yike’s core exhibit at the show was its powerful strain matrix, built on an integrated "industry-academia-medical-research" closed-loop system.
At the event, Bioyitech’s star strain – Bifidobacterium animalis subsp. lactis F1-7 – became a focal point for international buyers. It not only covers gut health and weight management, but also demonstrates outstanding efficacy in blood glucose management, liver health, and even emotional well being. This "multi effect from one strain" precisely addresses modern consumers’ urgent need for comprehensive health solutions.
Targeting the widespread issue of metabolic syndrome, Bioyitech’s "Jiang Xiaoyi" series – Purineed™ & SugaRite™ probiotic blends – showed strong market foresight. These blends, clinically tested in tertiary hospitals for uric acid and blood glucose management, were developed based on clinical evidence, directly solving the long standing industry pain point of "unsubstantiated functional claims". As Li Jiadong, General Manager of Zhongchuang Yike, said on site: "Single ingredients can no longer support product competitiveness. Only by providing clinically proven, differentiated ingredients can we help brand clients break through the red ocean."
Technological Breakthrough: Postbiotics Reshape Application Scenarios and Industry Boundaries
If clinical strains are the foundation of Zhongchuang Yike, then its postbiotics showcase demonstrates its keen sense of technological innovation. In the 2026 industry trends, postbiotics – thanks to their excellent thermal stability and long lasting effects – have become the key to breaking through the application limitations of probiotics.
Looking Ahead: A Technology Driven Blueprint for Metabolic Health
Vitafoods Europe 2026 was not just a product exhibition; it was a preview of the industry’s future. With the widespread use of GLP 1 drugs, consumer anxiety over "post medication rebound" and "muscle loss" has created new market demands. Meanwhile, the advent of an aging society has opened blue ocean opportunities for precision nutrition interventions targeting menopause, bone health, and cognitive function.
Backed by solid scientific research and sharp market insight, Bioyitech is redefining the value chain of the microbiome industry. Going forward, with the accumulation of more clinical data and expansion of application scenarios, Zhongchuang Yike is poised to take an even more important seat in the global metabolic health arena, leading Chinese microbiome enterprises to the center of the world stage.